Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 9/20 | 0.45 |
| ▸ | MTOR | P42345 | 6/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.38 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | TEK | Q02763 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL835475 | 1.00 | KDR (0.45) | KDRPDGFRBMTORPIK3CASLC16A3 | |
| SCHEMBL834693 | 0.89 | KDR (0.46) | KDRPDGFRBSLC16A3 | |
| SCHEMBL834694 | 0.89 | KDR (0.46) | KDRPDGFRBSLC16A3 | |
| SCHEMBL833839 | 0.88 | KDR (0.45) | KDRPDGFRBSLC16A3 | |
| SCHEMBL833840 | 0.88 | KDR (0.45) | KDRPDGFRBSLC16A3 | |
| SCHEMBL836858 | 0.87 | KDR (0.53) | KDRPDGFRBSLC16A3 | |
| SCHEMBL836650 | 0.87 | KDR (0.53) | KDRPDGFRBSLC16A3 | |
| SCHEMBL835062 | 0.87 | KDR (0.53) | KDRPDGFRBSLC16A3 | |
| SCHEMBL835627 | 0.85 | KDR (0.48) | KDRPDGFRBSLC16A3 | |
| SCHEMBL835084 | 0.85 | KDR (0.48) | KDRPDGFRBSLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099757-B1 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8383825-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120207810-A1 | Kinase Inhibitors | SPADA LON T (US) | 2012-08-16 | — | — | US | disclosed |
| US-8143410-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110263611-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2011-10-27 | — | — | US | disclosed |
| US-7915443-B2 | Sulfoximines as kinase inhibitors | ALLERGAN, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| WO-2010078393-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| EP-2099757-A2 | SULFOXIMINES AS KINASE INHIBITORS | Allergan, Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20090196906-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090099181-A1 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2008061236-A2 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263611-A1 | Kinase Inhibitors | PTK2, MAP3K6, MAP3K20 | KDR 51/4885PDGFRB 368/4885MTOR 85/4885 |
| US-20120207810-A1 | Kinase Inhibitors | PTK2, MAP3K6, MAP3K20 | KDR 51/4885PDGFRB 368/4885MTOR 85/4885 |
| US-20090196906-A1 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | KDR 51/4885PDGFRB 368/4885MTOR 85/4885 |
| US-20090099181-A1 | SULFOXIMINES AS KINASE INHIBITORS | SRC, PTK2B, TYRO3 | KDR 321/4885PDGFRB 409/4885MTOR 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.